Leadership: Page 2
-
Andrew Harnik via Getty Images
FDA’s future in MAHA hands: How leadership is changing the agency’s trajectory
Who’s in, who’s out and which key positions are still left to be filled in an agency upended.
By Alexandra Pecci • May 13, 2025 -
iStock via Getty Images
With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?
Community oncologists do their best to keep up with new treatments, but with the pace of cancer approvals, drugmakers need to team up with doctors on the front line.
By Michael Gibney • May 13, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Michael M. Santiago via Getty Images
RFK Jr.’s autism fixation hearkens back to his stance on vaccines
The head of HHS is seeking the “root causes” of autism spectrum disorder through a large government research project.
By Amy Baxter • May 9, 2025 -
Jacob Bell/PharmaVoice
Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications
With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.
By Michael Gibney • May 8, 2025 -
Kevin Dietsch via Getty Images
On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst
Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.
By Michael Gibney • May 6, 2025 -
Permission granted by Flagship Pioneering
Flagship’s latest venture reflects more than 25 years of leaping into the unknown
A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.
By Michael Gibney • April 24, 2025 -
Stephen Maturen via Getty Images
The fallout from UnitedHealth’s CEO slaying
Brian Thompson’s murder has raised questions about the cost of U.S. healthcare, embroiling insurers, drugmakers and PBMs in a battle for the future of the industry.
By PharmaVoice staff • April 15, 2025 -
Getty Images via Getty Images
Pharma’s capital allocation could shift as tariffs threaten an already fragile profit model
Major changes to the dynamics of the pharmaceutical ecosystem are making executive decisions even tougher.
By Michael Gibney • April 14, 2025 -
Permission granted by Michelle Werner
ProfileHer son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.
Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.
By Michael Gibney • April 8, 2025 -
Sarah Silbiger via Getty Images
Is the FDA ‘finished’? Leadership drain hits agency hard.
Amid widespread staff reductions at health agencies, a number of key officials have bid farewell to pharma’s top regulator.
By Amy Baxter • April 2, 2025 -
Permission granted by Pfizer
ProfileFormer Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’
Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.
By Michael Gibney • April 1, 2025 -
Permission granted by Novavax
ProfileThe industry heavyweight behind Novavax’s push to bounce back
As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.
By Alexandra Pecci • March 25, 2025 -
Stock via Getty Images
How pharma could feel the pain of a recession
Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.
By Meagan Parrish • March 21, 2025 -
Permission granted by Roche
Q&ARoche’s obesity deal with Zealand Pharma tees up rival for GLP-1s
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
By Amy Baxter • March 17, 2025 -
Andrew Harnik / Staff via Getty Images
Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings
HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.
By Michael Gibney • March 13, 2025 -
Kayla Bartkowski via Getty Images
How will Makary lead FDA amid workforce cuts and RFK Jr.s’ influence?
With President Trump’s nominee for FDA commissioner in Senate confirmation hearings, his approach to workforce cuts and other policies is under scrutiny.
By Amy Baxter • March 7, 2025 -
Courtesy of GSK Flickr page
How pharma CEO pay shifted for these 4 companies last year
Top executives saw big pay changes in a year defined by slower M&A and political uncertainty.
By Amy Baxter • March 3, 2025 -
Permission granted by Recursion
Q&AAI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration
Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.
By Michael Gibney • Feb. 27, 2025 -
George Clerk via Getty Images
Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer
Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.
By Ned Pagliarulo • Feb. 25, 2025 -
Stock via Getty Images
Its CEO died. The company scrapped a promising program. Now, for their 2nd act.
Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.
By Alexandra Pecci • Feb. 25, 2025 -
Getty Images via Getty Images
Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide
Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.
By Michael Gibney • Feb. 25, 2025 -
Chip Somodevilla via Getty Images
Kennedy’s MAHA agenda is tackling ‘conflicts of interest’ — and could take aim at FDA adcomms
Health agency job cuts and a newly-established MAHA commission leave many unanswered questions about potential reforms and impact on drug approvals.
By Amy Baxter • Feb. 24, 2025 -
Permission granted by Immunocore
Q&A // First 90 DaysLilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO
Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.
By Michael Gibney • Feb. 20, 2025 -
Stock via Getty Images
Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split
The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.
By Michael Gibney • Feb. 13, 2025 -
cagkansayin via Getty Images
With uncertainty roiling Big Pharma, execs are placing lower-risk bets
The market has been no less demanding for pharma giants as 2025 begins, but last year’s strategies are paying off.
By Michael Gibney • Feb. 6, 2025
Previous
